Bevacizumab in combination with first-line chemotherapy in XXXX with metastatic @entity14 : a meta-analysis.

@entity1 @entity14 @entity1349
BACKGROUND: Bevacizumab plays an important role in the treatment of @entity1 with metastatic @entity14 (mCRC). The aim of this study is to assemble current RCTs to analyze efficacy of adding bevacizumab to the most used combination first-line chemotherapy in mCRC @entity1 . METHODS: Pubmed, Web of Science, the Cochrane Library and Embase were systematically searched. Our primary endpoint was @entity1349 ( @entity1349 ), progression-free survival (PFS) and secondary endpoint was overall response rate (ORR). Hazard ratios (HRs) for PFS and @entity1349 and risk ratio (RR) for ORR were extracted from each trial. All these above were performed using a random-effects model and statistics was performed in StataSE 12.0. RESULTS: Seven Randomized controlled studies aggregating 3264 @entity1 were enrolled in our meta-analysis. @entity1349 , PFS and ORR were performed using a random-effects model. A therapeutic effect advantage was showed in Bevacizumab added to first-line chemotherapy with higher @entity1349 (HR = 0.67; 95% CI = 0.61-0.72;   - =0.000), PFS (HR = 0.67; 95% CI = 0.61-0.72;   - =0.000) compared with chemotherapy alone. Chemotherapy plus bevacizumab increased ORR (38.42% vs. 33.44%), showing statistically difference (RR = 1.17, 95% CI = 1.06-1.28, P = 0.001). CONCLUSION: Our meta-analysis shows that the addition of bevacizumab to first-line regimens can be beneficial in terms of @entity1349 , PFS and ORR compared with chemotherapy alone.
